Clearside Biomedical — Investor Presentation (March 2025)
44 slides from Clearside Biomedical's investor presentation, Mar 27, 2025
Slide 1: Corporate Presentation March 2025
Corporate Presentation March 2025 Exhibit 99.2
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,”
Slide 3: Delivering on the Potential of the Suprachoroidal Space
Delivering on the Potential of the Suprachoroidal Space Proven Leader in Suprachoroidal Delivery with Thousands of Injections Performed in the Clinic Validated Suprachoroidal Space (SCS) Delivery with Approved Product, Multiple Collaborations, and Comprehensive IP Portfolio Differentiated SCS Clinic
Slide 4: Clearside Suprachoroidal Product Development Pipeline Targeting Global Markets
Clearside Suprachoroidal Product Development Pipeline Targeting Global Markets 1XIPERE® (triamcinolone acetonide injectable suspension), for suprachoroidal use has received U.S. FDA Approval and is being commercialized by Bausch + Lomb. 2In licensed territories, Arctic Vision is responsible for clin
Slide 5: Multiple Validating Partnerships Expand Utilization of SCS Microinjector Technology
Multiple Validating Partnerships Expand Utilization of SCS Microinjector® Technology THERAPEUTIC TYPE INDICATION IND-ENABLING PHASE 1 PHASE 2 PHASE 3 APPROVAL PARTNER Bel-Sar Viral-like Drug Conjugate Choroidal Melanoma Sura-vec AAV Gene Therapy Diabetic Retinopathy (DR)* Sura-vec AAV Gene Therapy W
Slide 6: Core Competencies in Delivery & Formulation Drive Patented Technology
Core Competencies in Delivery & Formulation Drive Patented Technology DRUG PATENTS Administration of a variety of drugs to the suprachoroidal space by microinjection DISEASE PATENTS Methods of treating ocular disorders by SCS administration KEY INTELLECTUAL PROPERTY COMPONENTS Comprehensive IP portf
Slide 7: Proven Commercial Capabilities in Suprachoroidal Delivery
Proven Commercial Capabilities in Suprachoroidal Delivery Proprietary Microinjector with Significant Clinical Experience ISO Certified Commercial Scale Injector Manufacturing Capability Formulation Expertise Experience in Navigating the Drug/Device Regulatory Pathway 1st FDA Product Approved for SCS
Slide 8: Suprachoroidal Delivery via SCS Microinjector
Suprachoroidal Delivery via SCS Microinjector®
Slide 9: Delivering on the Potential of the Suprachoroidal Space: A Novel Approach to Drug Delivery
Delivering on the Potential of the Suprachoroidal Space (SCS®): A Novel Approach to Drug Delivery for Retinal Diseases Injectate Flows to the Back of the Eye and Diffuses into the Retina
Slide 10: Benefits for Patients and Physicians Using SCS Microinjector Delivery
Benefits for Patients and Physicians Using SCS Microinjector® Delivery Enhanced Safety Much lower risk of endophthalmitis as direct contact to immune system vs intravitreal injection Injectate Flows to Back of the Eye Reduced risk of floaters, snow globe effect, or other visual disturbances No Impla
Slide 11: SCS Microinjector: Drug/Device Combination with Proven Versatility
Abbreviations: UME = uveitic macular edema; DME = diabetic macular edema; DR = diabetic retinopathy; Sources: Clearside data on file | 1Kurup, et. al, Macula Society 2021 Safety of the Suprachoroidal Injection Procedure Utilizing SCS Microinjector® across Three Retinal Disorders. SCS Microinjector®:
Slide 12: Straightforward Suprachoroidal Injection Technique
Straightforward Suprachoroidal Injection Technique Hold the microinjector perpendicular to the ocular surface Ensure firm contact with sclera by maintaining a dimple throughout injection Inject slowly over 5 – 10 seconds Perpendicular Dimple Slow Source: Clearside July 24, 2024 KOL Webinar
Slide 13: Clearside Needle Size Equivalent to Most Commonly Used Intravitreal Injections
Clearside Needle Size Equivalent to Most Commonly Used Intravitreal Injections and Smaller than Other TKIs in development 22G 25G 30G Outer Diameter of the Needle Relative to the Ocular Tissue Inner Diameter of the Needle Drug Product Passage 30G needle results in less damage to the ocular tissue wo
Slide 14: CLS-AX (axitinib injectable suspension)
CLS-AX (axitinib injectable suspension) New mechanism of action with potential for longer duration of effect for the treatment of wet AMD
Slide 15: Leveraging a Highly Potent Pan-VEGF Inhibitor with Suprachoroidal Delivery
Leveraging a Highly Potent Pan-VEGF Inhibitor with Suprachoroidal Delivery Axitinib High potency TKI with pan-VEGF receptor inhibition Proprietary CLS-AX Small Molecule Suspension Formulation Clearside formulation expertise Delivery via SCS Microinjector® Utilizes the same administration device as F
Slide 16: Axitinib is a Highly Potent, Highly Selective Pan-VEGF Inhibitor
Axitinib is a Highly Potent, Highly Selective Pan-VEGF Inhibitor Inhibits ALL VEGF Receptors (VEGFR-1, VEGFR-2, VEGFR-3) Intrinsic pan-VEGF inhibition through receptor blockade More active than anti-VEGF-A in in-vitro angiogenesis model1-2 Approved AMD treatments are focused VEGF-A inhibitors Tyrosi
Slide 17: Positioning CLS-AX for Real-World Success in the $12 Billion Wet AMD Market
Positioning CLS-AX for Real-World Success in the $12 Billion Dollar Wet AMD Market1 1Annual financial reports from Regeneron Pharmaceuticals, Inc. and Genentech/Roche 2Dosing regimens are per respective product labels EYLEA® and EYLEA HD® are registered trademarks of Regeneron Pharmaceuticals| LUCEN
Slide 18: ODYSSEY Phase 2b Topline Data Summary
i PHASE 2 TOPLINE DATA SUMMARY CIDYSSEY
Slide 19: ODYSSEY Phase 2b Clinical Trial Overview
Trial Objectives: Evaluated safety, efficacy & duration of CLS-AX in participants with wet AMD Primary Outcomes: Mean change in BCVA from Baseline to Week 36; Safety & tolerability Secondary Outcomes: Other changes in visual function and retinal imaging, including CST; Need for supplemental treatmen
Slide 20: ODYSSEY Trial Design
* Disease Activity Assessments (DAA): Conducted at Week 12 through 32 to determine need for supplemental treatment. # In CLS-AX arm, following 3 loading doses of aflibercept and initial dose of CLS-AX at Baseline, participants will receive CLS-AX at least every 24 weeks unless more frequently requir
Slide 21: Intervention-Free Rates By Week Up to Each Visit
Intervention–Free Rates By Week Up to Each Visit Two-Thirds of Participants Dosed with CLS-AX Reached Six Months Without Additional Treatment Calculation accounts for missed treatments; time of initial administration of study drug shown as month 0 on figure. Intervention-free rate calculation: if pa
Slide 22: Comparative TKI Intervention Free Rate Over Months
Comparative TKI Intervention Free Rate Over 6 Months Results based on publicly available information provided by each company as of February 2025. Data presented above is not based on head-to-head studies and may not be directly comparable. EyePoint is pooled 2mg and 3mg;.
Slide 23: Weeks Before and After CLS-AX Consistently Reduced the Frequency of Injections
24 Weeks Before and After CLS-AX Consistently Reduced the Frequency of Injections Comparison of Wet AMD Treatments Pre- and Post- Randomization Injection post Baseline includes re-dosing with CLS-AX and/or supplementary treatment with aflibercept. Injection frequency reduction calculated by the aver
Slide 24: CLS-AX Demonstrated Stable BCVA and CST Over Weeks
CLS-AX Demonstrated Stable BCVA and CST Over 36 Weeks ^Study drug administration for aflibercept participants given at Weeks 12, 20 and 28. Abbreviations: BCVA = best corrected visual acuity; CST = central subfield thickness as reported by the reading center; SEM = standard error of the mean P-value
Slide 25: CLS-AX Demonstrated a Positive Safety Profile
CLS-AX Demonstrated a Positive Safety Profile Safety Profile Well-tolerated safety profile through 36 weeks including after mandatory re-dosing of CLS-AX at Week 24 No Serious Adverse Events (SAEs) No ocular SAEs or treatment-related SAEs: No drug or procedure related ocular SAEs No reported drug or
Slide 26: CLS-AX Now Phase 3 Ready Based on Positive ODYSSEY Data in Wet AMD
CLS-AX Now Phase 3 Ready Based on Positive ODYSSEY Data in Wet AMD Enrolled Only Difficult-to-Treat Participants with Active Disease Achieved Primary Outcome Maintaining Stable BCVA with Repeat Dosing Compelling Intervention-Free Rates Abbreviation: Wet AMD = neovascular age-related macular degenera
Slide 27: CLS-AX Phase 3 Program Current Plans
CLS-AX Phase 3 Program Current Plans Phase 3 plans are in development and subject to change
Slide 28: CLS-AX Phase 3 To Feature the Flexible Dosing of a Biologic with the Duration of a TKI
CLS-AX Phase 3 To Feature the Flexible Dosing of a Biologic with the Duration of a TKI Two pivotal, non-inferiority trials in treatment naïve participants CLS-AX flexible dosing is an important differentiation vs other TKI programs Similar to Phase 3 trial design of EYLEA HD and VABYSMO in maintenan
Slide 29: Sub-Group Analysis: Supports Enrolling Treatment Naïve Patients in the Phase 3 Program
Participants Solely Re-Dosed with CLS-AX at Week 24 Without Prior Intervention Sub-Group Analysis: Supports Enrolling Treatment Naïve Patients in the Phase 3 Program Analysis includes CLS-AX participants solely re-dosed with CLS-AX at Week 24 who never received rescue therapy vs. aflibercept compara
Slide 30: Sub-Group Analysis: Supports Phase 3 Design Excluding Non-Disease Related Changes
Excluding Observations with ≥10 Letter Change from the Previous Visit in BCVA Without a Corresponding 25 Micron Change in CST Sub-Group Analysis: Supports Phase 3 Design that Excludes Participants with Non-Disease Related Changes in Visual Acuity Prior to Randomization Key Insights for Phase 3 BCVA
Slide 31: CLS-AX Phase 3 Program Designed to Reduce Regulatory Risk and Maximize Commercial Opportunity
CLS-AX Phase 3 Program Designed to Potentially Reduce Regulatory Risk and Maximize Commercial Opportunity in Wet AMD Aflibercept CLS-AX Sham Procedure Abbreviations: SCR = Screening Visit; RC = Randomization Criteria; R/B = Randomization/Baseline; PE = Primary Endpoint; Participants will be randomiz
Slide 32: CLS-AX Phase 3 Non-Inferiority Study Design in Wet AMD
CLS-AX Phase 3 Non-Inferiority Study Design in Wet AMD Designed to Optimize Success Strategies to Reduce Variability: Minimize enrollment of highly variable participants at Screening Participants must have 20/80 to 20/32 AND CST <500 at diagnosis At Week -4 following three aflibercept loading doses,
Slide 33: Unique Ability to Re-Dose CLS-AX vs Rescue Supports Regulatory & Commercial Strategy
Unique Ability to Re-Dose CLS-AX vs Rescue Supports Regulatory & Commercial Strategy Why Flexible Dosing Matters Planned Phase 3 Approach Wet AMD is a chronic disease requiring numerous injections to maintain vision and stabilize the disease We know from clinical experience that patients require dif
Slide 34: CLS-AX Phase 3 Designed to Compete with Currently Approved Drugs
VABYSMO® CLS-AX OTX-TKI EYP-1901 Non-inferiority 2 2 1 2 Multiple dosing 2 2 1 2 Flexible dosing Y Y N N Tested Interval in Months 2 to 4 3 to 6 6 6 Rescue / Redosing Redosing Redosing Rescue Rescue Study population optimization N Y Y N CLS-AX Phase 3 Designed to Compete with Currently Approved Drug
Slide 35: CLS-AX Potentially Versatile and Commercially Appealing Label
WET AMD Intended Dosing Interval Range (Weeks) CLS-AX Potentially Versatile and Commercially Appealing Label with Large Total Addressable Market Based on Planned 3-6 Month Dosing Flexibility Q4W Q8W Q12W Q16W Q20W Q24W Dosing based on publicly available information provided by each company as of Mar
Slide 36: Why We Believe CLS-AX Should Be the Preferred TKI
Why We Believe CLS-AX Should Be the “Preferred TKI” Efficacy Profile vs. Other TKIs Potential SCS Safety Advantages Rigorous Phase 2 Trial Design Should Reduce Phase 3 Risks facing other TKIs Physician/Commercially Preferred Target Label (3 - 6 months) As flexible as VABYSMO and EYLEA HD and as dura
Slide 37: Pipeline Expansion Opportunity in Geographic Atrophy
Pipeline Expansion Opportunity in Geographic Atrophy
Slide 38: Geographic Atrophy is a Choroidal Disease
Choroidal Hypoxia Theory and Choriocapillaris are Damaged First Geographic Atrophy is a Choroidal Disease and an Advanced Form of Age-Related Macular Degeneration (AMD) Choriocapillaris endothelial cells damage with ghost vessels before any significant RPE changes Choriocapillaris (CC) vascular dens
Slide 39: Small Molecule Can Access the Diseased Area of the RPE and Choroid
Larger molecules cannot get through Bruch’s membrane. Therefore, if given intravitreally, it can only treat the RPE side. Aging intensifies disease actions and even peptides might not be able to get through. Small Molecule Can Access the Diseased Area of the RPE and Choroid Images modified from Hamm
Slide 40: Potential Advantages of Suprachoroidal Delivery in Geographic Atrophy
Potential Advantages of Suprachoroidal Delivery in Geographic Atrophy In-office procedure Small molecules may have better efficacy than current therapies SCS may be ideal delivery for gene therapy as subretinal is too invasive and intravitreal delivery lacks efficacy with a high risk of inflammation
Slide 41: Geographic Atrophy Program Focused on Small Molecule Suspensions
Geographic Atrophy Program Focused on Small Molecule Suspensions Small Molecule Suspensions Can treat both sides of the Bruch’s membrane (Retina, RPE and Choroid) Higher concentration of drug in the choroid 1. Improve choroidal perfusion Blood flow improvement can improve retinal function directly a
Slide 42: Summary
Summary <a ° cree jee . . a a ee ee ee oe | ee ereee
Slide 43: Differentiated late-stage ophthalmology company with a platform of assets
Differentiated late-stage ophthalmology company with a platform of assets Patented SCS Microinjector® delivers agents directly to the back of the eye Validated technology with multiple partners Aligned with the FDA on the Phase 3 program designed to support a commercially appealing label Potential p
Slide 44: TM
Nasdaq: CLSD TM
Clearside Biomedical — Investor Presentation (March 2025) on 6ix